These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Immunohistochemical study on the expression of c-erbB2 oncoprotein in breast tumors].
    Author: Zhang Z, Xu G, Liu S.
    Journal: Zhonghua Zhong Liu Za Zhi; 1997 Jul; 19(4):287-9. PubMed ID: 11038761.
    Abstract:
    OBJECTIVE: To examine the relationship between oncoprotein c-erbB2 over-expression and prognosis of primary breast tumor patients, and find if it can be used as a prognostic indicator. METHODS: Eighty-five cases of paraffin-embedded specimens were used for immunohistochemical study. RESULTS: Over-expression of c-erbB2 was observed in none of the 7 benign breast tumors. Twenty-three out of 78 cases of breast cancer showed over-expression with a positive rate of 29.4%. Over-expressed c-erbB2 oncoprotein was not detected in 80% of patients with negative lymph node. In clinical stage III patients, 71% of them over-expressed c-erbB2. The expression of c-erbB2 and estrogen receptor(ER) was inversely correlated in 67% of breast cancer patients. Oncoprotein c-erbB2 over-expression had no correlation with lymph node status(P > 0.05), but was closely correlated to clinical staging(P < 0.05). CONCLUSION: Patients with over-expression of c-erbB2 oncoprotein showed poor prognosis. The c-erbB2 may be used for predicting the prognosis of breast cancer patients.
    [Abstract] [Full Text] [Related] [New Search]